Sandoz has petitioned the US Court of Appeals for the Federal Circuit for an en banc rehearing of a recent decision that stands to keep its Erelzi (etanercept-szzs) biosimilar rival to Amgen’s Enbrel off the market for a further nine years, claiming that the ruling provides a “playbook” for originators to extend their patents beyond their legitimate terms.
The Novartis subsidiary obtained US Food and Drug Administration approval for Erelzi four years ago but has been held off...






